Safety Profile of IBD Therapeutics: Infectious Risks

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Over the last decade, the medical treatment of inflammatory bowel disease (IBD) has been revolutionized, with increasing use of both immunomodulatory and biologic medications. Corticosteroids have increasingly been shown to increase the risk of serious and opportunistic infections, both independently and in combination with immunomodulator and biologic agents. There are limited data on the infectious risk of immunomodulators. It is unclear if anti-tumor necrosis factor-α agents increase overall infectious risk in patients with IBD, but the available literature has demonstrated an increased risk of opportunistic infections, particularly in terms of tuberculosis and histoplasmosis. Combination therapy likely increases the risk of opportunistic infections in patients with IBD but this has not yet been conclusively proved.

Original languageEnglish (US)
Pages (from-to)115-133
Number of pages19
JournalMedical Clinics of North America
Volume94
Issue number1
DOIs
StatePublished - Jan 2010

Fingerprint

Inflammatory Bowel Diseases
Opportunistic Infections
Safety
Immunologic Factors
Therapeutics
Histoplasmosis
Biological Factors
Adrenal Cortex Hormones
Tuberculosis
Tumor Necrosis Factor-alpha

Keywords

  • Anti-tumor necrosis factor
  • Corticosteroids
  • Immunomodulator
  • Infection
  • Inflammatory bowel disease

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Safety Profile of IBD Therapeutics : Infectious Risks. / Afif, Waqqas; Loftus, Jr, Edward Vincent.

In: Medical Clinics of North America, Vol. 94, No. 1, 01.2010, p. 115-133.

Research output: Contribution to journalReview article

@article{d028fcd7989544189d1ed48b3d1ea7ee,
title = "Safety Profile of IBD Therapeutics: Infectious Risks",
abstract = "Over the last decade, the medical treatment of inflammatory bowel disease (IBD) has been revolutionized, with increasing use of both immunomodulatory and biologic medications. Corticosteroids have increasingly been shown to increase the risk of serious and opportunistic infections, both independently and in combination with immunomodulator and biologic agents. There are limited data on the infectious risk of immunomodulators. It is unclear if anti-tumor necrosis factor-α agents increase overall infectious risk in patients with IBD, but the available literature has demonstrated an increased risk of opportunistic infections, particularly in terms of tuberculosis and histoplasmosis. Combination therapy likely increases the risk of opportunistic infections in patients with IBD but this has not yet been conclusively proved.",
keywords = "Anti-tumor necrosis factor, Corticosteroids, Immunomodulator, Infection, Inflammatory bowel disease",
author = "Waqqas Afif and {Loftus, Jr}, {Edward Vincent}",
year = "2010",
month = "1",
doi = "10.1016/j.mcna.2009.08.016",
language = "English (US)",
volume = "94",
pages = "115--133",
journal = "Medical Clinics of North America",
issn = "0025-7125",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Safety Profile of IBD Therapeutics

T2 - Infectious Risks

AU - Afif, Waqqas

AU - Loftus, Jr, Edward Vincent

PY - 2010/1

Y1 - 2010/1

N2 - Over the last decade, the medical treatment of inflammatory bowel disease (IBD) has been revolutionized, with increasing use of both immunomodulatory and biologic medications. Corticosteroids have increasingly been shown to increase the risk of serious and opportunistic infections, both independently and in combination with immunomodulator and biologic agents. There are limited data on the infectious risk of immunomodulators. It is unclear if anti-tumor necrosis factor-α agents increase overall infectious risk in patients with IBD, but the available literature has demonstrated an increased risk of opportunistic infections, particularly in terms of tuberculosis and histoplasmosis. Combination therapy likely increases the risk of opportunistic infections in patients with IBD but this has not yet been conclusively proved.

AB - Over the last decade, the medical treatment of inflammatory bowel disease (IBD) has been revolutionized, with increasing use of both immunomodulatory and biologic medications. Corticosteroids have increasingly been shown to increase the risk of serious and opportunistic infections, both independently and in combination with immunomodulator and biologic agents. There are limited data on the infectious risk of immunomodulators. It is unclear if anti-tumor necrosis factor-α agents increase overall infectious risk in patients with IBD, but the available literature has demonstrated an increased risk of opportunistic infections, particularly in terms of tuberculosis and histoplasmosis. Combination therapy likely increases the risk of opportunistic infections in patients with IBD but this has not yet been conclusively proved.

KW - Anti-tumor necrosis factor

KW - Corticosteroids

KW - Immunomodulator

KW - Infection

KW - Inflammatory bowel disease

UR - http://www.scopus.com/inward/record.url?scp=70450172575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70450172575&partnerID=8YFLogxK

U2 - 10.1016/j.mcna.2009.08.016

DO - 10.1016/j.mcna.2009.08.016

M3 - Review article

C2 - 19944801

AN - SCOPUS:70450172575

VL - 94

SP - 115

EP - 133

JO - Medical Clinics of North America

JF - Medical Clinics of North America

SN - 0025-7125

IS - 1

ER -